Checkpoint Therapeutics Stock Analysis

Checkpoint Stock Analysis Notes

About 30.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.82. Checkpoint Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 6th of December 2022. Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Checkpoint Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. For more info on Checkpoint Therapeutics please contact III CFA at 781 652 4500 or go to https://checkpointtx.com.

Checkpoint Therapeutics Investment Alerts

Checkpoint Therapeutics Upcoming and Recent Events

Checkpoint Largest EPS Surprises

View All Earnings Estimates

Checkpoint Therapeutics Environmental, Social, and Governance (ESG) Scores

Checkpoint Stock Institutional Investors

Note, although Checkpoint Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Checkpoint Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 135.75 M.

Checkpoint Profitablity

Management Efficiency

Checkpoint Therapeutics has return on total asset (ROA) of (6.3394) % which means that it has lost $6.3394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.2038) %, meaning that it created substantial loss on money invested by shareholders. Checkpoint Therapeutics' management efficiency ratios could be used to measure how well Checkpoint Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Checkpoint Therapeutics' Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 3.76 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (10.53). Change To Liabilities is likely to gain to about 22.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 12.9 M in 2025.

Technical Drivers

As of the 27th of February, Checkpoint Therapeutics shows the mean deviation of 3.94, and Risk Adjusted Performance of (0.02). Checkpoint Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Checkpoint Therapeutics Price Movement Analysis

Checkpoint Therapeutics Insider Trading Activities

Checkpoint Therapeutics Outstanding Bonds

Checkpoint Therapeutics Predictive Daily Indicators

Checkpoint Therapeutics Corporate Filings

Checkpoint Therapeutics Forecast Models

Checkpoint Therapeutics' time-series forecasting models are one of many Checkpoint Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Checkpoint Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Checkpoint Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Checkpoint shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Checkpoint Therapeutics. By using and applying Checkpoint Stock analysis, traders can create a robust methodology for identifying Checkpoint entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Checkpoint analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Checkpoint analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Checkpoint Therapeutics stock analysis indicators help investors evaluate how Checkpoint Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Checkpoint Therapeutics shares will generate the highest return on investment. By understating and applying Checkpoint Therapeutics stock analysis, traders can identify Checkpoint Therapeutics position entry and exit signals to maximize returns.

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.